US2012270749A1PendingUtilityA1

Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia

25
Assignee: GEBAUER MATHIASPriority: Nov 6, 2009Filed: Nov 4, 2010Published: Oct 25, 2012
Est. expiryNov 6, 2029(~3.3 yrs left)· nominal 20-yr term from priority
G01N 33/6893C12Q 1/6883C12Q 2600/158G01N 2800/2842C12Q 2600/136
25
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method of identifying a compound involved in pain, the use of C1qb nucleic acid or C1qb protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Claims

exact text as granted — not AI-modified
1 . A method of identifying a compound involved in pain, the method comprising the steps of:
 a) providing a test system comprising C1qb nucleic acid or C1 qb protein or a functionally active variant of a C1qb protein,   b) contacting the test system with a test compound, and   c) determining the effect of the test compound on the test system, wherein the test compound is identified as a compound involved in pain when a significant effect of the test compound on the test system relative to a control is detected.   
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , wherein the compound involved in pain is a cellular compound which is part of the signal transduction pathway of the C1qb gene and/or the C1qb protein. 
     
     
         4 . The method of  claim 3 , wherein the compound involved in pain alters signal transduction upstream or downstream the C1qb protein. 
     
     
         5 . The method of  claim 3 , wherein the compound involved in pain alters signal transduction upstream or downstream the C1qb gene. 
     
     
         6 . The method of  claim 1 , wherein the compound involved in pain binds to a cellular compound which is part of the signal transduction pathway of the C1qb gene and/or the C1qb protein. 
     
     
         7 . The method of  claim 6 , wherein the compound involved in pain inhibits signal transduction upstream or downstream the C1qb gene. 
     
     
         8 . The method of  claim 6 , wherein the compound involved in pain inhibits signal transduction upstream or downstream the C1qb protein. 
     
     
         9 . The method of  claim 1 , wherein the test system is in a cell. 
     
     
         10 . The method of  claim 1 , wherein the method is a high-through-put method. 
     
     
         11 . The method of  claim 1 , wherein the pain is neuropathic pain. 
     
     
         12 - 14 . (canceled) 
     
     
         15 . A method of diagnosing algesia, comprising the steps of
 a) determining the level expression of the C1qb gene in a subject's sample, and   b) identifying the subject as algesic if the level of expression of the C1qb gene is increased in the subject's sample relative to a control sample.   
     
     
         16 . The method of  claim 5 , wherein the compound alters expression of the C1qb gene. 
     
     
         17 . The method of  claim 6 , wherein the compound involved in pain binds to the C1qb nucleic acid. 
     
     
         18 . The method of  claim 7 , wherein the compound involved in pain inhibits expression of the C1qb gene. 
     
     
         19 . The method of  claim 8 , wherein the compound involved in pain binds to the C1qb protein.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.